Loading...
Loading...
PMN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 4.4M |
| Operating I/L | -4.4M |
| Other Income/Expense | 13.7M |
| Interest Income | 0.0M |
| Pretax | 9.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 9.3M |
ProMIS Neurosciences, Inc. is a Canadian company specializing in precision medicine solutions for neurodegenerative diseases such as Alzheimer's, ALS, and MSA. The company's proprietary discovery platform utilizes ProMIS and Collective Coordinates algorithms to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, targeting toxic oligomers in AD; PMN267, addressing ALS and Parkinson's disease; and PMN442, focusing on MSA. By developing monoclonal antibodies for these targets, ProMIS Neurosciences aims to provide effective treatments for these debilitating conditions, potentially generating revenue through the sale of therapeutic products and licensing agreements.
